Search
forLearn
5 / 801 resultsResearch
5 / 482 results
research Skin permeability and transdermal delivery route of 50-nm indomethacin-loaded PLGA nanoparticles
50-nm nanoparticles are better at penetrating skin and targeting hair follicles for drug delivery than 100-nm ones.
research Thymol-loaded PLGA nanoparticles: an efficient approach for acne treatment
Thymol-loaded nanoparticles are a promising, natural treatment for acne that avoids antibiotics and preserves healthy skin bacteria.
research Promoting effect of type 17 collagen production by chlorogenic acid using PLGA nanoparticles in the human epidermal keratinocyte cell
Encapsulating chlorogenic acid in nanoparticles boosts type 17 collagen production, potentially aiding skin care.
research In vivo evaluation of the efficacy, toxicity and biodistribution of PLGA-DMSA nanoparticles loaded with itraconazole for treatment of paracoccidioidomycosis
Itraconazole-loaded nanoparticles are more effective and less toxic for treating fungal infections than conventional oral itraconazole.
research Development of minoxidil-loaded double emulsion PLGA nanoparticles for the treatment of hair loss
Minoxidil-loaded nanoparticles effectively promote hair regrowth and are safe for use.
Community Join
5 / 1000+ resultscommunity New and Interesting HairLoss Studies/Papers/Reviews
Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.
community Polydopamine Synergizes with Quercetin Nanosystem to Reshape the Perifollicular Microenvironment for Accelerating Hair Regrowth in Androgenetic Alopecia.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community PP405 Update and My Take on Pelage
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.